Editorial: Advances and challenges in nanomedicine

Abstract

Overall, nanomedicine has the potential to revolutionize the way we detect and treat damage to the human body. Although nanomedicines have demonstrated significant therapeutic advantages for a multitude of medical applications, their translation has not progressed as rapidly as the plethora of positive preclinical results would have suggested (Luxenhofer et al., 2014; Sercombe et al., 2015; Hare et al., 2017; Hua et al.). The experimental development of nanomedicines is continually progressing at a fast pace, however significant challenges still exist in promoting these platforms into clinically feasible therapies. Therefore, continued translational success will require communication and collaboration between experts involved in all stages of pharmaceutical development of nanotechnologies, including pharmaceutical design and manufacturing, cellular interactions and toxicology, as well as preclinical and clinical evaluation (Hua et al.).